



South Asian Academy of Ophthalmology

Under aegis of South Asian Academy of Ophthalmology (SAO)

# TIPS IN PRACTICE

**WHICH ? WHEN ?? & HOW ???**

(Ocular Surface Disease / Anti Glaucoma Treatment / Anti-VEGF Injections)

**Date :** 20<sup>th</sup> July 2024 • **Time :** 10:30 am - 7.30 pm

**Venue :** Hall Jacaranda, India Habitat Centre (IHC), New Delhi



## Chairperson



Dr. Rajvardhan Azad

## Convenors



Dr. Lalit Verma



Dr. Namrata Sharma



Dr. Tariq Reza Ali

Supported by:





# TIPS IN PRACTICE

**Which ? When ?? & How ???**

**( Ocular Surface disease Management /  
Anti Glaucoma Treatment / Anti-VEGF Injections )**

Under aegis of South Asian Academy of Ophthalmology ( SAO )

**Date :** 20<sup>th</sup> July 2024 • **Time :** 10:30 am - 07:30 pm

**Venue :** Hall Jacaranda ( India Habitat Centre ) New Delhi

## Outline

Session	Timing
Ocular Surface disease management	10:30 am – 12:00 noon
Anti Glaucoma Treatment	12:00 noon – 1:30 pm
<b>Lunch :- 1:30 pm – 2:30 pm</b>	
Anti VEGF Injections ( Conventional )	2:30 pm – 4:00 pm
Newer Anti VEGFs - I	4:00 pm – 5:30 pm
<b>Tea Break :- 05:30 – 06:00 pm</b>	
Newer Anti VEGFs – II	6:00 pm – 7:30 pm
<b>Cocktails &amp; Dinner :- 07:30 pm onwards</b>	

## Session I

**Ocular Surface Disease Management : All that you wanted to know : 10:30 am – 12:00 am**

<b>Chairpersons</b>	Dr. Jeewan S. Titiyal, Dr. Ritu Arora, Dr. Rishi Mohan, Dr. Namrata Sharma, Dr. Aditi Ghosh
<b>Moderator</b>	Dr. M Vanathi

S.No.	Title	Speaker
1	Ocular Allergies an Enigma	Dr. Rajat Jain
2	Dry eye after Cataract surgery : Is there any role of Prophylactic lubricants ?	Dr. Rushad Shroff
3	Dry eye after Refractive surgery : Do we give lubricants in all cases ?	Dr. Tushar Grover
4	Dry eye after anti glaucoma medication : Catch 22 situation !	Dr. Dewang Angmo
5	Role of Topical cyclosporine in dry eye	Dr. Rajesh Sinha
6	Meibomian gland disease : Which device to use for diagnosis and treatment ?	Dr. Jaya Gupta
7	Dry eye and systemic disease	Dr. Shikha Jain
8	Intracameral Prophylaxis in Cataract Surgery	Dr. Namrata Sharma
9	Nanomicellar topical cyclosporine : What everyone must know	Dr. Namrata Sharma

( Each talk 8 mins )



Tips in Practice  
Which ? When ?? & How ???

## Session II

Anti Glaucoma Treatment : 12:00 am – 1:30 pm

Chairpersons	Dr. Harsh Kumar, Dr. Vishnu Gupta, Dr. J S Bhalla
Moderator	Dr. Harsh Kumar

S.No.	Title	Speaker
1	Which anti glaucoma medications should we start in an OAG ( when field has mild/ moderate/severe damage )	Dr. Harsh Kumar
2	How to modify depending on existing eye problems like corneal changes/ uveitis/ macular edema	Dr. Taru Dewan
3	Which investigations will help us determine if a glaucoma suspect needs treatment	Dr. Tanuj Dada
4	OAG with moderate damage and mild field loss on two medications, What next ? MIGS -stent / BANG / KDB ?	Dr. Dewang Angmo
5	OAG with advanced damage and cataract controlled on medications : Combined surgery/ only Cataract surgery	Dr. Dewang Angmo

( Each talk 12 mins )

Lunch Break :- 1:30 pm – 2:30 pm

## Session III

Conventional Anti VEGF ; 2:30 pm – 4:00 pm

Chairpersons	Dr. Rajvardhan Azad, Dr. Rajpal Vohra, Dr. Shashank Gupta, Dr. Rajeev Jain
Moderator	Dr. Dinesh Talwar

S.No.	Title	Speaker
1	DME with Planned cataract surgery : Time to see the difference	Dr Awaneesh Upadhayay
2	Deep diving into RVO Management	Dr. Ashish Vaidya
3	Role of Anti-VEGFs in the management of PDR	Dr. Chinmay Sahu
4	RAZUMAB : The FIRST & the BEST Biosimilar	Dr. Avnindra Gupta
5	Anti VEGF : Interesting cases	Dr. Vinod Aggarwal
6	Why I prefer Aflibercept in wAMD & DME ?	Dr. Mallika Goyal
7	Molecular differentiation of Anti -VEGF's	Dr. Gagan Bhatia
8	I still use Avastin	Dr. Rohan Chawla
9	My choice of Anti-VEGF	Dr. Prakhar Goyal

( Each talk 8 mins )



Tips in Practice  
Which ? When ?? & How ???

### Newer Anti VEGFs - I ; 4:00 pm - 5:30 pm

<b>Chairpersons</b>	Brig. (Dr.) S K Mishra , Dr. Obuli Ramachandran, Dr. Vinod Aggarwal, Dr. Avnindra Gupta, Dr. Harish HS
<b>Moderators</b>	Dr. Lalit Verma, Dr. Kunal Rana

S.No.	Title	Speaker
1	Changing treatment paradigm for PCV management - An nAMD subset.	Dr. Bhuvan Chanana
2	Reimagining drying and durability with Brolucizumab	Dr. Vikram Koundanya
3	Breaking the clinical dilemmas in DME management - Should you treat early and aggressively	Dr. Chaitra Jayadev
4	Breaking the barriers in the management of nAMD	Dr. Raja Narayanan
5	Brolucizumab - An agent of efficacy, safety and durability in DME ( An R + R Experience )	Brig. (Dr.) S K Mishra
6	My experience with Brolucizumab and OCTA as a Potential guider	Dr. Arnab Das
7	Which Antioxidants in ARMD ?	Dr. Arindam Chakravarti
8	Brolucizumab : A game changer in the treatment of nAMD and DME	Dr. Justus Garweg (Switzerland)

Tea Break :- 05:30 pm - 06:00 pm

### Newer Anti VEGFs - II ; 6:00 pm - 07:30 pm

New Paradigm in the management of nAMD and DME  
( Time for chANGe )

<b>Chairperson &amp; Moderator</b>	Dr. Lalit Verma
<b>Panelists</b>	Dr. Neeraj Sanduja, Dr. Saurabh Arora, Dr. Ruchir Tewari, Dr. Aniruddha Agarwal (UAE), Dr. Nikhil Pal, Dr. Vikram Koundanya

S.No.	Title	Speaker
1	Context setting & Why Vabysmo?	Dr. Lalit Verma
2	Time for chANGe: Clinical insights and real world evidence with Vabysmo in nAMD and DME.	Dr. Aniruddha Agarwal (UAE)
3	Faricimab for nAMD and DME-Interesting cases	Dr. Nikhil Pal
4	Eyes on Vabysmo: Intersting Cases in nAMD and DME	Dr. Vikram Koundanya
5	Closing Remarks	Dr. Lalit Verma

Cocktails & Dinner :- 07:30 pm onwards